Viral Clearance Market

The global viral clearance market is expected to reach USD 724.5 million by 2023 from USD 271.2 million in 2018, at a CAGR of 21.7%. The viral clearance market is rapidly emerging with many regional as well as international companies. In 2017, Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France) held a share of approximately 70.0% of the viral clearance market.

Wuxi Biologics (Cayman) (China) dominated the global viral clearance market in 2017. The company’s revenue increased from USD 148.9 million in 2016 to USD 239.6 in 2017; this has helped the company reinforce its position in the viral clearance market. The company offers its services to over 200 companies globally, which include 13 of the top 20 global pharmaceutical companies. Wuxi maintains 12 viral clearance suites to cater to the growing customer needs worldwide. Additionally, the company has a comprehensive database mining strategy to design optimal process parameters and steps for viral clearance to avoid ineffective steps. Wuxi Biologics implements a multichannel sales and marketing approach to build awareness about its brand. It is also a part of various industry trade conferences dedicated to biologics development and manufacturing worldwide.

To know about the assumptions considered for the study download the pdf brochure

Merck KGaA (Germany) is one of the leading players in the viral clearance market. The company’s Process Solutions business unit offers over 15,000 products and services including single-use manufacturing, filtration, chromatography, purification, virus reduction, drug delivery compounds, and engineering and validation services. R&D is a key area of focus for Merck-it invested USD 272.3 million in R&D activities in 2017. The company strives to expand its product portfolio, build a better network for increasing its customer base, and enter new markets. The company mainly focuses on achieving organic growth to expand its geographic presence in international markets.

Charles River Laboratories International Inc. (US) is one of the major players in the viral clearance market. The company provides viral clearance studies and viral safety testing services through its Manufacturing Support business segment. The Manufacturing Support segment generated revenue of USD 384 million in 2017 which accounted for 20.7% of its total revenue. The company was involved in the research and development of about 80% of the drugs that were approved by the U.S. FDA in 2017. It mainly focuses on achieving inorganic growth by entering into partnerships and acquisitions. In January 2018, for instance, the company acquired KWS BioTest (UK) to expand its existing discovery capabilities in the field of immunology. As part of its marketing and sales strategy, it focuses on participating in seminars, symposiums, and exhibitions to increase awareness as well as showcase its products and services. For instance, in October 2017, the company attended the 2nd Viral Clearance and Viral Safety Summit in California, US.

Some of the other players competing in this market are Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).

Related Reports:

Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]